Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
King's College Hospital NHS Trust
St. Jude Children's Research Hospital
Mayo Clinic
Jonsson Comprehensive Cancer Center
St. Jude Children's Research Hospital
Washington University School of Medicine
Ohio State University Comprehensive Cancer Center
Technical University of Munich
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
Washington University School of Medicine
National Cancer Institute (NCI)
Hospital Sirio-Libanes
Huashan Hospital
Washington University School of Medicine
University of Ulm
Stanford University
Sun Yat-sen University
Roswell Park Cancer Institute
Northwestern University
Children's Oncology Group
Huashan Hospital
Huashan Hospital
Huashan Hospital
Jonsson Comprehensive Cancer Center
University Hospital, Caen
Clinica Universidad de Navarra, Universidad de Navarra
McGill University Health Centre/Research Institute of the McGill University Health Centre
Chiang Mai University
Institut Claudius Regaud
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
First Affiliated Hospital of Fujian Medical University
Dana-Farber Cancer Institute
Kasr El Aini Hospital
Alliance for Clinical Trials in Oncology
Activartis Biotech
Merck Sharp & Dohme LLC
Duke University
INSYS Therapeutics Inc
Duke University
National Cancer Institute (NCI)
Barretos Cancer Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Radiation Therapy Oncology Group